

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background	9
2. Objective and scope	10
3. Selection of agents for review	11
4. Data for the <i>Monographs</i>	11
5. Meeting participants	12
6. Working procedures	13
B. SCIENTIFIC REVIEW AND EVALUATION	14
1. Exposure data	15
2. Studies of cancer in humans	16
3. Studies of cancer in experimental animals	20
4. Mechanistic and other relevant data	23
5. Summary	26
6. Evaluation and rationale	27
References	31
GENERAL REMARKS	33
MALARIA	41
1. Exposure Data	41
1.1 Taxonomy, structure, and biology of <i>Plasmodium</i>	41
1.2 Epidemiology of <i>Plasmodium</i> infection	45
2. Cancer in Humans	53
2.1 Burkitt lymphoma	54
2.2 Kaposi sarcoma	72
2.3 Cancers at other sites	74
2.4 Susceptible populations	75
3. Cancer in Experimental Animals	75
3.1 Mouse	75
3.2 Rat	77

4. Mechanistic and Other Relevant Data.....	77
4.1 Malaria and the host immune system	77
4.2 Biological properties of <i>P. falciparum</i> antigens relevant to immune dysfunction.....	87
4.3 Other infectious agents associated with falciparum malaria and human cancer.....	91
4.4 <i>Plasmodium</i> infection in experimental animals	97
4.5 Susceptible populations.....	97
4.6 Mechanisms of lymphomagenesis.....	97
5. Summary of Data Reported.....	99
5.1 Exposure Data.....	99
5.2 Human carcinogenicity data	99
5.3 Animal carcinogenicity data	100
5.4 Mechanistic and other relevant data.....	100
6. Evaluation and Rationale.....	101
6.1 Cancer in humans	101
6.2 Cancer in experimental animals	101
6.3 Mechanistic and other relevant data.....	101
6.4 Overall evaluation	101
References.....	101

INTRODUCTION TO POLYOMAVIRUSES.....	121
1. Discovery	121
2. Taxonomy and phylogeny	123
3. Structure of the virion	123
4. Genomic organization, gene products, and replication	124
5. Viral life-cycle	127
6. Host range.....	128
References.....	128

SIMIAN VIRUS 40.....	133
1. Exposure Data	133
1.1 Host range and tissue tropism.....	133
1.2 Methods for the detection of SV40 infection	133
1.3 Epidemiology of infection.....	134
2. Cancer in Humans.....	142
2.1 Prospective studies.....	142
2.2 Case–control studies	153
2.3 Susceptible populations.....	162
2.4 Case series.....	167
3. Cancer in Experimental Animals	169
3.1 Infection with SV40.....	169
3.2 Infection with SV40 DNA	182
3.3 Transgenic mouse models.....	182
3.4 Carcinogenicity of SV40 in combination with asbestos	190

4. Mechanistic and Other Relevant Data	190
4.1 Transforming capacity of SV40	190
4.2 Biological properties and regulation of SV40 viral proteins relevant to carcinogenesis	191
4.3 <i>In vivo</i> and <i>in vitro</i> evidence for a role for SV40 in human malignancies	194
4.4 Interaction between SV40 and potential cofactors	198
4.5 Transgenic models for cancers associated with SV40 infection	198
4.6 Susceptible human populations	198
4.7 Mechanistic considerations in relation to carcinogenesis	199
5. Summary of Data Reported	201
5.1 Exposure data	201
5.2 Human carcinogenicity data	201
5.3 Animal carcinogenicity data	202
5.4 Mechanistic and other relevant data	203
6. Evaluation	203
6.1 Cancer in humans	203
6.2 Cancer in experimental animals	203
6.3 Overall evaluation	203
6.4 Rationale	203
References	204
BK POLYOMAVIRUS	215
1. Exposure Data	215
1.1 Cell and tissue tropism	215
1.2 Methods for the detection of BKV	215
1.3 Epidemiology of BKV infection	217
2. Cancer in Humans	221
2.1 Background	222
2.2 Cancer of the prostate	223
2.3 Cancer of the colon	227
2.4 Haematological malignancies	228
2.5 Neuroblastoma	229
2.6 Cancer of the brain	229
2.7 Cancer of the head and neck	229
2.8 Cancer of the bladder	230
2.9 Cancer of the ovary	230
2.10 Precursors to cancer of the cervix	230
2.11 Cancers of the renal pelvis and kidneys	230
2.12 Cancer risk among patients with polyomavirus-associated nephropathy (PVAN)	231
3. Cancer in Experimental Animals	231
3.1 Hamster	231
3.2 Mouse	240
3.3 Rat	240
3.4 Hamsters injected with BKV DNA	241
3.5 Hamsters injected with BKV and <i>c-Ha-ras</i> DNA	241
3.6 Transgenic mouse models of BKV T-antigen with natural viral promoter	241

4. Mechanistic and Other Relevant Data.....	241
4.1 Transforming capacity of BKV.....	241
4.2 Relevant biological properties of BKV viral proteins.....	243
4.3 Association of BKV with human tumours.....	243
4.4 Transgenic models for cancers associated with BKV infection.....	246
4.5 Susceptible human populations.....	246
4.6 Mechanistic considerations.....	247
5. Summary of Data Reported.....	249
5.1 Exposure data.....	249
5.2 Human carcinogenicity data.....	249
5.3 Animal carcinogenicity data.....	250
5.4 Mechanistic and other relevant data.....	250
6. Evaluation.....	251
6.1 Cancer in humans.....	251
6.2 Cancer in experimental animals.....	251
6.3 Overall evaluation.....	251
References.....	251

JC POLYOMAVIRUS.....	261
1. Exposure Data.....	261
1.1 Cell and tissue tropism.....	261
1.2 Methods for the detection of JCV.....	261
1.3 Epidemiology of JCV infection.....	262
2. Cancer in Humans.....	265
2.1 Background.....	266
2.2 Cancer of the colorectum.....	266
2.3 Non-Hodgkin lymphoma (NHL).....	272
2.4 Cancer of the brain.....	273
2.5 Cancer of the bladder.....	274
2.6 Childhood malignancies.....	274
2.7 Other cancers.....	276
2.8 Intervention studies.....	277
2.9 Susceptible populations.....	281
3. Cancer in Experimental Animals.....	281
3.1 Monkey.....	281
3.2 Hamster.....	281
3.3 Rat.....	286
3.4 Transgenic mouse models.....	287
4. Mechanistic and Other Relevant Data.....	289
4.1 Transforming capacity of JCV.....	289
4.2 Relevant biological properties of JCV viral proteins.....	289
4.3 <i>In vivo</i> and <i>in vitro</i> evidence for a role of JCV in human malignancies.....	290
4.4 Transgenic models for cancers associated with JCV infection.....	296
4.5 Susceptible human populations.....	296
4.6 Mechanistic considerations.....	296

5. Summary of Data Reported.....	298
5.1 Exposure data.....	298
5.2 Human carcinogenicity data.....	298
5.3 Animal carcinogenicity data.....	299
5.4 Mechanistic and other relevant data.....	299
6. Evaluation.....	300
6.1 Cancer in humans.....	300
6.2 Cancer in experimental animals.....	300
6.3 Overall evaluation.....	300
References.....	300
MERKEL CELL POLYOMAVIRUS.....	309
1. Exposure Data.....	309
1.1 Cell and tissue tropism.....	309
1.2 Methods for the detection of MCV.....	309
1.3 Epidemiology of infection.....	311
1.4 Diseases associated with MCV.....	314
2. Cancer in Humans.....	314
2.1 Background.....	314
2.2 Case-control studies.....	314
2.3 Case series.....	318
2.4 Susceptible populations.....	327
3. Cancer in Experimental Animals.....	327
4. Mechanistic and Other Relevant Data.....	327
4.1 Transforming capacity of MCV.....	327
4.2 Relevant biological properties of MCV-encoded viral proteins.....	327
4.3 <i>In vivo</i> and <i>in vitro</i> evidence for a role of MCV in human malignancies.....	329
4.4 Interaction between MCV and other potential cofactors.....	339
4.5 Susceptible populations.....	339
4.6 Transgenic models for cancers associated with MCV infection.....	340
4.7 Mechanisms of carcinogenesis.....	340
5. Summary of Data Reported.....	343
5.1 Exposure data.....	343
5.2 Human carcinogenicity data.....	343
5.3 Animal carcinogenicity data.....	343
5.4 Mechanistic and other relevant data.....	343
6. Evaluation.....	344
6.1 Cancer in humans.....	344
6.2 Cancer in experimental animals.....	344
6.3 Overall evaluation.....	344
References.....	344
LIST OF ABBREVIATIONS.....	351

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.

